glp 1 for kidney disease SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Disease: Evolving Evidence and Clinical Application glp-1 kidney disease news GLP-1s

Chavez-MacGregor, M

This product has not been evaluated by the MHRA or FDA

Pillars 7 , 100080 (2023)

With antiamyloid antibodies Leqembi (lecanemab) and Kisunla (donanemab) now FDAapproved for early Alzheimers, attention is turning to combination strategies that address multiple disease pathways

Storage checklist Lyophilized vials: -20 degrees C long-term, 2-8 degrees C short-term Reconstituted vials: 2-8 degrees C only, use within 30 days Never freeze reconstituted solution Protect from light at all stages Label every vial with reconstitution date and concentration Discard any vial exposed to room temperature for more than 12 hours Injection technique and site selection Cagrilintide is administered subcutaneously, meaning the needle goes into the fat layer just beneath the skin